Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Alvotech, Fuji Pharma Sign Commercialization Agreement | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Alvotech, Fuji Pharma Sign Commercialization Agreement

For the exclusive partnership and supply to commercialize Alvotech’s ustekinumab biosimilar (Stelara) in Japan

By: Betsy Louda

, Contract Pharma

Alvotech and Fuji Pharma have entered into a binding agreement for the exclusive partnership and supply to commercialize Alvotech’s ustekinumab biosimilar (Stelara®) in Japan. Alvotech and Fuji Pharma recently announced Fuji´s ~US$50 million investment into Alvotech that further strengthens the partnership between the companies and reflects a long-term commitment from both parties. 

Under the terms of the agreement, Alvotech will assume responsibility for full development and commercial supply, out of its new state-of-the-art manufacturing facility in Reykjavik, Iceland. Alvotech will receive an upfront payment of $ 4.6 million as a part of the transaction, with rights to receive total milestone payments up to $20 million.
 
Ustekinumab is a mAb biosimilar to Janssen pharmaceuticals’ Stelara®, which is a human interleukin-12 and -23 antagonist indicated for the treatment of plaque psoriasis, psoriatic arthritis and Crohn disease. The brand Stelara® generated approximately $5.2 billion worldwide in net revenues in 2018 according to J&J reporting.
 
Alvotech‘s initial pipeline consists of six biosimilar monoclonal antibodies and fusion proteins aimed at treating severe immune, inflammatory conditions, that improve the quality of life for patients around the world. Alvotech’s fully vertically integrated business model has established a platform that will add new products each year and over time create a substantial portfolio of high quality, high value products.
 
Aztiq Pharma, led by Robert Wessman (Alvotech‘s founder as well as Chairman and CEO of Alvogen) is a majority shareholder of Alvotech, while other shareholders are sister company Alvogen and Fuji Pharma.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics